Rigel Pharmaceuticals, Inc. (RIGL) Stock

Rigel Pharmaceuticals, Inc. (RIGL) is a Healthcare stock trading at $32.92 (as of 2026-06-18), with a market capitalization of $564.13M and a trailing P/E of 1.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rigel Pharmaceuticals develops and licenses small-molecule medicines for hematologic disorders, cancer, and rare immune diseases. Its portfolio includes Tavalisse for adult chronic immune thrombocytopenia, with additional clinical-stage programs such as fostamatinib, R289, and R552, alongside research and license collaborations with companies including AstraZeneca, BerGenBio, and Daiichi Sankyo.

Valuation — source: SEC EDGAR (first-party)
Price$32.92
Market Cap$564.13M
P/E Ratio1.7
EV / EBITDA5.0
Price / Book1.54
Price / Sales2.06
DCF Value (model)$102.69
DCF Upside vs Price211.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$294.28M
Net Margin124.7%
Return on Equity91.1%
Debt / Equity0.11
Current Ratio2.62
Revenue Growth (YoY)64.1%
EPS Growth (YoY)1960.6%
Financial Health — source: SEC EDGAR
Altman Z-Score1.91 (grey)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E1.7
Sector P/E (Healthcare)21.0
Industry P/E (Pharmaceutical Products)17.3
vs Sector-91.7%
vs Industry-90.0%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($47.83M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEORaul R. Rodriguez
Employees162
CountryUS
IPO Date2000-11-29

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Aquestive Therapeutics, Inc. (AQST)
  • GH Research PLC (GHRS)
  • Spyre Therapeutics, Inc. (SYRE)
  • MapLight Therapeutics, Inc. (MPLT)
  • Anavex Life Sciences Corp. (AVXL)
  • Esperion Therapeutics, Inc. (ESPR)
  • Jade Biosciences, Inc. (JBIO)
RIGL earnings history · RIGL institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.